Medical Marijuana, Inc. investment AXIM® Biotechnologies looks to expand impressive intellectual property portfolio with patent on cannabinoid chewing gum for migraines.
Leading cannabinoid research and new drug development company AXIM® Biotechnologies recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO).
The provisional patent application is for a patent on a chewing gum composition comprising of cannabinoids and parthenolide (feverfew extract) for treatment of symptoms of migraines. This provisional application establishes AXIM®’s filing date for the patent and gives AXIM® one year to file a formal patent application for their invention.
AXIM® Biotechnologies has already built a strong intellectual property portfolio with 5 issued patents, 12 pending patents, and 28 trademarks. The company is looking to expand on this IP portfolio with additional new drugs and consumer products formulated with cannabinoids, including this cannabinoid-based treatment for migraine symptoms.
The company is currently in development or trials for cannabinoid chewing gum treatments for symptoms related to multiple sclerosis, chemotherapy, AIDS, drug-related psychosis, and restless leg syndrome, with more on the way.
“AXIM is best known for its patent on chewing gum containing cannabinoids and our flagship CBD chewing gum product, CanChew+,” said AXIM CEO John W. Huemoeller II.“With this patent application and AXIM’s current cannabis chewing gum products currently in development, we plan to bring a variety of treatment options to the market.”
With this new provisional patent application, AXIM® plans to develop a cannabinoid chewing gum that contains cannabidiol (CBD) and/or cannabigerol (CBG), as well as feverfew extract, for the treatment of symptoms that often accompany migraines, such as headache, pain, nausea, and light sensitivity.
Feverfew has been proven to relieve and prevent symptoms of migraines. The company is looking to combine these effects with the benefits of cannabinoids like CBD and CBG for a novel way for migraine sufferers to find quick relief.
The new formulation will be delivered through AXIM®’s proprietary sustained-release chewing gum delivery technology to release active ingredients in a controlled manner into the oral cavity for a fast but lasting onset of effects.
There is currently no permanent cure for migraines, so treatments are aimed at relief of symptoms. The market for migraine treatments has been growing as global incidence has increased. According to Grand View Research, Inc., the global migraine treatment market size is expected to reach $7.8 billion by 2025. Although the migraine market is highly competitive, many migraine sufferers are looking for alternative treatments like CBD that don’t feature that harsh synthetic chemicals found in most current treatment options.
“As a company of firsts, Medical Marijuana, Inc. is proud to support AXIM as it files this patent application for the first-ever cannabis-based gum formulated to treat the symptoms of migraines,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Studies have estimated that migraines affect roughly 38 million people in the U.S. and the market currently lacks an effective natural treatment option for those people.”
You can learn more about AXIM® Biotechnologies, including its latest new drug developments, here, or visit our news feed for the latest from across our portfolio of companies.
